Karlan, Beth Y.

Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2

Monk, B. J., Poveda, A., Vergote, I., Raspagliesi, F., Fujiwara, K., Bae, D.-S., Oaknin, A., Ray-Coquard, I., Provencher, D. M., Karlan, B. Y., et al. (2016) · Gynecologic Oncology

Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapy

Cited by 98

MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations

Lubinski, J., Kotsopoulos, J., Moller, P., Pal, T., Eisen, A., Peck, L., Karlan, B. Y., Aeilts, A., Eng, C., Bordeleau, L., et al. (2024) · JAMA Oncology

BRCA gene mutations in cancerMRI in cancer diagnosis

Cited by 82

Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32, 295 women

EMBRACE, Rebbeck, T. R., HEBON, Friebel, T. M., Mitra, N., Wan, F., Chen, S., Andrulis, I. L., Apostolou, P., Arnold, N., et al. (2016) · Breast Cancer Research

BRCA gene mutations in cancerMultiple and Secondary Primary Cancers

Cited by 71

Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence Variations

Kotsopoulos, J., Gronwald, J., Huzarski, T., Møller, P., Pal, T., McCuaig, J. M., Singer, C. F., Karlan, B. Y., Aeilts, A., Eng, C., et al. (2024) · JAMA Oncology

BRCA gene mutations in cancerMultiple and Secondary Primary Cancers

Cited by 56

Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis

Metcalfe, K., Huzarski, T., Gronwald, J., Kotsopoulos, J., Kim, R., Moller, P., Pal, T., Aeilts, A., Eisen, A., Karlan, B., et al. (2024) · British Journal of Cancer

BRCA gene mutations in cancerGlobal Cancer Incidence and Screening

Cited by 46

Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer

Walsh, C. S., Kamrava, M., Rogatko, A., Kim, S., Li, A., Cass, I., Karlan, B., & Rimel, B. J. (2021) · PLOS ONE

Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapy

Cited by 27

Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation

Kotsopoulos, J., Gronwald, J., Huzarski, T., Aeilts, A., Randall Armel, S., Karlan, B., Singer, C. F., Eisen, A., Tung, N., Olopade, O., et al. (2023) · Breast Cancer Research and Treatment

BRCA gene mutations in cancerCancer Risks and Factors

Cited by 26

Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer

Kar, S. P., Considine, D. P. C., Tyrer, J. P., Plummer, J. T., Chen, S., Dezem, F. S., Barbeira, A. N., Rajagopal, P. S., Rosenow, W. T., Moreno, F., et al. (2021) · Human Genetics and Genomics Advances

Genetic Associations and EpidemiologyBRCA gene mutations in cancer

Cited by 18

Evolving paradigms in research and Care in Ovarian Cancers

Karlan, B. Y., Alvarez, R. D., & Strauss, J. F. (2016) · Obstetrics & Gynecology

Ovarian cancer diagnosis and treatmentBRCA gene mutations in cancer

Cited by 14